WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 HighlightsNet product revenue of $12.0 million, an increase of 32.9% compared to $9.0 million in the prior-year period. Gross margin of 80%, compared to 71% in the prior-year period, an improvement of approximately 920 basis points, reflecting the lower Ameluz® cost structure established following the closing of the strategic transaction with Biofrontera AG in October 2025 (the “Strategic Transaction”). Net loss of $0.6 million, or $(0.05) per share, compared to a net loss of $5.3...

Please see attached document.Attachment2026 CHL Corporate Restructuring

Correction: Due to a technical error, the announcement published on 13 August 2026 contained an incorrect interest rate for the period from 15 May 2026 to 15 August 2026. The correct interest rate for the period from 15 May 2026 to 15 August 2026 was 3.383% per annum, consisting of a 1.1% margin and a 2.283% three-month EURIBOR rate. The interest period dates have been corrected in accordance with the Prospectus. On 18 December 2025, Vytis Reno Loans 2025-1 Designated Activity Company (DAC) admitted to trading on the Nasdaq Baltic bond list a bond issue with an aggregate nominal value of EUR 81.2 million (ISIN LT0000136418). Under this bond issue, investors are paid annual interest calculated as the sum of a 1.1 per cent margin and the 3-month EURIBOR rate. Please be informed that, for the interest period from 15 December 2025 to 15 May...

Winter Park, Florida, Aug. 13, 2026 (GLOBE NEWSWIRE) — Tron Inc. (Nasdaq: TRON) (the “Company”), the largest publicly traded holder of TRON (TRX) tokens, today announced a major strategic initiative to deepen its integration in the TRON DAO ecosystem and expand into value-add infrastructure businesses capable of generating recurring on-chain revenue.  The Company plans to pursue election as a top-tier Super Representative (“SR”) for the TRON network. SR nodes (27 in total) operate collaboratively to secure the TRON blockchain, produce blocks, validate transactions, and participate in on-chain community governance. In 2025, the TRON network generated total block production rewards of approximately 122 million TRX for the SRs, as well as voting rewards of approximately 1.5 billion TRX distributed to the 27 SRs and the other SR Partners. The...

Record quarterly revenue driven by continuing strong growth in SSi Mantra unit sales FORT LAUDERDALE, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) — via IBN – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and six months ended June 30, 2026.  The Company also filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, with the Securities and Exchange Commission on August 13, 2026. Second Quarter 2026 OverviewRevenue increased 39.4% to $13.9 million from $10.0 million in the second quarter of 2025. Gross margin equaled 50.9%, compared to 59.1% in the second quarter of 2025. Gross profit...

LAS VEGAS, Aug. 13, 2026 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE) (“Live Ventures” or the “Company”), a diversified holding company, today announced financial results for its fiscal third quarter ended June 30, 2026.  Fiscal Third Quarter 2026 Key Highlights:Revenue was $108.9 million, compared to $112.5 million in the prior-year period, with year-over-year revenue growth in three of the Company’s four operating segments Gross margin expanded approximately 10 basis points to 34.1%, compared to 34.0% in the prior-year period Operating income was $5.3 million, compared to operating income of $8.0 million in the prior-year period Net loss was $1.1 million and loss per share was $0.34, compared to net income of $5.4 million and diluted earnings per share (“EPS”) of $1.24 in the prior-year periodPrior-year period...

– Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled – – Commencement of Phase 2b Long-Term Extension Study to assess Halneuron® reduction in pain over three months of treatment – – Appointment of Iain Dukes, D.Phil., Venture Partner at OrbiMed, as Chair of Scientific Advisory Board – – Announced Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Dogwood Therapeutics and its CVR Holders – ALPHARETTA, Ga., Aug. 13, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced financial results for the second...